<DOC>
	<DOCNO>NCT00149604</DOCNO>
	<brief_summary>The purpose study determine whether estrogen specifically promote reduction fat abdominal region weight loss and/or prevent accumulation abdominal fat weight gain .</brief_summary>
	<brief_title>AFTER : Altering Fat Through Estrogen Raloxifene</brief_title>
	<detailed_description>The general aim study determine whether estrogen-based hormone therapy ( HT ) postmenopausal woman reduce accumulation abdominal visceral fat whether contribute factor effect estrogens cardiovascular risk factor . An additional aim determine whether raloxifene , selective estrogen receptor modulator ( SERM ) suggest safe alternative estrogen prevention osteoporosis , exert similar effect estrogen fat distribution . Mechanisms possible regional difference regulation fat metabolism estrogen-sufficient vs estrogen-deficient state investigate , extent estrogen status change visceral adiposity associate change risk coronary artery disease ( CAD ) Type 2 diabetes mellitus ( DM ) . The hypothesis test include 1 ) reduction total fat mass total abdominal visceral fat significantly great woman treat HT raloxifene receive placebo treatment , 2 ) accumulation total fat mass total abdominal visceral fat 12-month follow-up period significantly less woman HT raloxifene receive placebo treatment , 3 ) reduction visceral fat mass associate increased sensitivity insulin breakdown fat whole body , independent enhance effect HT raloxifene insulin action , 4 ) change risk factor CAD Type 2 DM closely associate change visceral adiposity change total fat mass measure regional adiposity , independent addition effect HT raloxifene risk factor . To meet aim , reduction visceral fat induce 108 postmenopausal woman 6-month program supervise exercise training plus mild caloric restriction . Participants randomize receive HT , raloxifene , placebo . The drug treatment continue , fat reduction program cease , 12-month follow-up period . Risk factor CAD Type 2 DM insulin sensitivity term breakdown fat total body regional adipose tissue evaluate treatment follow-up period ( risk factor ) . For purpose application , HT refers regimen involve daily conjugate estrogen , woman uterus , tri-monthly progestin treatment .</detailed_description>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>postmenopausal woman age 5070 yr healthy , determined medical history , physical examination , blood chemistry , grade exercise stress test monitoring blood pressure ECG good cognitive function . contraindication estrogen raloxifene treatment , include history active breast cancer estrogendependent neoplasm , acute liver disease , undiagnosed vaginal bleeding , active history blood clot disorder mild severe cognitive impairment , indicate MMSE score &lt; 26 clinically significant abnormal rest electrocardiogram ( ECG ) , angina and/or ECG evidence acute myocardial ischemia maximal exercise stress test rest blood pressure 150 mmHg systolic 90 mmHg diastolic leave bundle branch block , AV block great first degree , clinically significant arrhythmias congestive heart failure pulmonary emboli previous 6 month aortic stenosis chronic infection orthopedic problem would interfere participation exercise program</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>abdominal adiposity</keyword>
	<keyword>lipolysis</keyword>
</DOC>